Chronic pain scores among medium and high pain subgroups were significantly lower following MDMA-AT.

Serotonergic antidepressants appear to weaken psilocybin’s effects relative to a nonserotonergic antidepressant.

In ... participants with treatment-resistant depression, psilocybin at a single dose of 25 mg, but not 10 mg, reduced depression scores significantly ... over a period of 3 weeks.

To conclude, the present study provides the first evidence that MD may have therapeutic value in adults diagnosed with ADHD or experiencing severe ADHD complaints.

How best to design psychedelic-assisted therapy treatments, from initial screening to post-treatment integration sessions.

Careful research in this area could significantly impact the treatment of one of the most severe and socially debilitating psychiatric disorders.

These results suggest that microdosers may need to periodically suspend their microdosing routine to avoid tolerance.

I want to give you a peek into the underside of the iceberg of psychedelic research. Let’s step away from the headlines, broaden our scope, and dive into the frontier of this field.

New research into the effects of psychedelics on brain blood flow.

We here show that lasting changes in trait mindfulness following psilocybin administration are positively associated with intensity of the mystical-type experience.

This review indicates an association between psychedelic therapy and significant reduction of depressive symptoms at several time points.

COMPASS’ program will be the first ever Phase 3 program of psilocybin therapy.

Ecstasy use was also associated with significantly higher odds of better self-reported overall health.

On the overall harm scale, N2O scored 6, just above magic mushrooms (psilocybin) while ‘poppers’ scored 5. Together these are the three lowest drugs on the overall harm scale.

The question on everybody’s lips was – ‘how can we implement psychedelics into our pre-existing healthcare systems safely, legally, and responsibly?’.